U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. Reports, Manuals, & Forms
  4. Reports
  5. Economic Impact Analyses of FDA Regulations
  6. Summary: Amendments to 21 CFR Part 3 - Product Jurisdiction (Proposed Rule)
  1. Economic Impact Analyses of FDA Regulations

Summary: Amendments to 21 CFR Part 3 - Product Jurisdiction (Proposed Rule)

The Food and Drug Administration (FDA or Agency) is proposing to amend its regulations concerning the classification of products as biological products, devices, drugs, or combination products, and their assignment to Agency components for premarket review and regulation. This proposed rule would update the regulations to clarify the scope of the regulations, streamline and clarify the appeals process, align the regulations with more recent legislative and regulatory measures, update advisory content, and otherwise clarify the regulations, including updates to reflect Agency practices and policies. These changes are intended to enhance regulatory clarity and efficiency.

Regulatory Impact Analysis

Federal Register: 83 FR 22428, May 15, 2018

Docket: FDA-2004-N-0191

Back to Top